Literature DB >> 30353424

Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

P W Rosario1,2, G Mourão3, M R Calsolari3.   

Abstract

PURPOSE: This study evaluated the recurrence rate in patients with papillary thyroid carcinoma (PTC) and minimal extrathyroidal extension (mETE) who had low thyroglobulin (Tg) after total thyroidectomy, and therefore, did not receive radioactive iodine (RAI).
METHODS: This was a prospective study including 182 patients with tumors ≤ 4 cm and mETE without aggressive histology or clinically apparent lymph node involvement (cN0pNx). After thyroidectomy, all patients had nonstimulated Tg ≤ 0.3 ng/ml, negative antithyroglobulin antibodies (TgAb), and neck ultrasonography (US) showing no anomalies. Because of these results, the patients were not submitted to RAI.
RESULTS: The time of follow-up ranged from 24 to 132 months (median 72 months). One hundred and seventy-eight patients (97.8%) continued to have nonstimulated Tg ≤ 0.3 ng/ml and negative US. Four patients (2.2%) exhibited an increase in Tg and lymph node metastases (structural recurrence). After surgery, these patients obtained nonstimulated Tg < 1 ng/ml and no apparent tumor was detected by the imaging methods.
CONCLUSION: The results suggest that patients with mETE and without other adverse features, who have low nonstimulated Tg and negative neck US after thyroidectomy, do not require ablation with RAI.

Entities:  

Keywords:  Minimal extrathyroidal extension; Papillary thyroid carcinoma; Postoperative nonstimulated thyroglobulin; Radioiodine

Mesh:

Substances:

Year:  2018        PMID: 30353424     DOI: 10.1007/s40618-018-0969-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

1.  Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma.

Authors:  Camille Buffet; Jean Louis Golmard; Catherine Hoang; Christophe Trésallet; Laurence Du Pasquier Fédiaevsky; Hélène Fierrard; André Aurengo; Fabrice Menegaux; Laurence Leenhardt
Journal:  Eur J Endocrinol       Date:  2012-05-30       Impact factor: 6.664

2.  Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma.

Authors:  Pedro Weslley Souza Rosário; Sérgio de Faria; Luciano Bicalho; Maria Flávia Gatti Alves; Michelle Aparecida Ribeiro Borges; Saulo Purisch; Eduardo Lanza Padrão; Leonardo Lamego Rezende; Alvaro Luís Barroso
Journal:  J Ultrasound Med       Date:  2005-10       Impact factor: 2.153

3.  Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.

Authors:  Pedro Weslley Rosario; Augusto Flávio Campos Mineiro Filho; Brenda Sá Senna Prates; Lívia Cristina Oliveira Silva; Maria Regina Calsolari
Journal:  Thyroid       Date:  2012-10-10       Impact factor: 6.568

4.  Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance.

Authors:  Pedro Weslley S Rosário; Frederico F Ribeiro Maia; Tales Alvarenga Fagundes; Flávio Palhano Vasconcelos; Ludmilla David Cardoso; Saulo Purisch
Journal:  Arq Bras Endocrinol Metabol       Date:  2005-03-07

5.  The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer.

Authors:  Iain J Nixon; Ian Ganly; Snehal Patel; Frank L Palmer; Monica M Whitcher; Robert M Tuttle; Ashok R Shaha; Jatin P Shah
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

6.  Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases.

Authors:  Xiao-Min Yu; Yin Wan; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg       Date:  2011-10       Impact factor: 12.969

7.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.

Authors:  Pedro Weslley Rosario; Arthur Cezar Malard Xavier; Maria Regina Calsolari
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

8.  A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.

Authors:  Eyal Robenshtok; Ravinder K Grewal; Stephanie Fish; Mona Sabra; R Michael Tuttle
Journal:  Thyroid       Date:  2013-03-18       Impact factor: 6.568

9.  Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study.

Authors:  Pedro W Rosário; Wilson C Tavares; Michelle A R Borges; Juan Bernard N Santos; Maria Regina Calsolari
Journal:  Endocr Pract       Date:  2014-04       Impact factor: 3.443

10.  Guidelines for the management of thyroid cancer.

Authors:  Petros Perros; Kristien Boelaert; Steve Colley; Carol Evans; Rhordi M Evans; Georgina Gerrard Ba; Jackie Gilbert; Barney Harrison; Sarah J Johnson; Thomas E Giles; Laura Moss; Val Lewington; Kate Newbold; Judith Taylor; Rajesh V Thakker; John Watkinson; Graham R Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2014-07       Impact factor: 3.478

View more
  4 in total

1.  Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?

Authors:  R Forleo; N Fralassi; F Maino; M Capezzone; L Brilli; T Pilli; S Cantara; M G Castagna
Journal:  J Endocrinol Invest       Date:  2020-05-09       Impact factor: 4.256

2.  Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.

Authors:  Robert Seifert; Michael Andreas Schäfers; Barbara Heitplatz; Laura Kerschke; Burkhard Riemann; Benjamin Noto
Journal:  J Nucl Med       Date:  2021-03-26       Impact factor: 11.082

3.  Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC).

Authors:  Nadia Bouzehouane; Pascal Roy; Myriam Decaussin-Petrucci; Mireille Bertholon-Grégoire; Chantal Bully; Agnès Perrin; Helene Lasolle; Jean-Christophe Lifante; Françoise Borson-Chazot; Claire Bournaud
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

4.  An immediate postoperative response to therapy assessment can help avoid unnecessary RAI therapy.

Authors:  Hao Zhao; Chun-Hao Liu; Yue Cao; Li-Yang Zhang; Ya Zhao; Xin Zhang; Yan-Song Lin; Yu Xia; Yue-Wu Liu; Hong-Feng Liu; Xiao-Yi Li
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.